Regeneron Pharmaceuticals (REGN) Equity Ratio (2016 - 2025)
Historic Equity Ratio for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 0.77.
- Regeneron Pharmaceuticals' Equity Ratio fell 86.53% to 0.77 in Q4 2025 from the same period last year, while for Dec 2025 it was 0.77, marking a year-over-year decrease of 86.53%. This contributed to the annual value of 0.77 for FY2025, which is 86.53% down from last year.
- Latest data reveals that Regeneron Pharmaceuticals reported Equity Ratio of 0.77 as of Q4 2025, which was down 86.53% from 0.77 recorded in Q3 2025.
- In the past 5 years, Regeneron Pharmaceuticals' Equity Ratio ranged from a high of 0.79 in Q1 2024 and a low of 0.67 during Q1 2021
- Moreover, its 5-year median value for Equity Ratio was 0.78 (2022), whereas its average is 0.76.
- Within the past 5 years, the most significant YoY rise in Regeneron Pharmaceuticals' Equity Ratio was 1580.9% (2021), while the steepest drop was 1247.62% (2021).
- Over the past 5 years, Regeneron Pharmaceuticals' Equity Ratio (Quarter) stood at 0.74 in 2021, then increased by 5.13% to 0.78 in 2022, then rose by 1.21% to 0.79 in 2023, then fell by 0.99% to 0.78 in 2024, then fell by 0.87% to 0.77 in 2025.
- Its Equity Ratio was 0.77 in Q4 2025, compared to 0.77 in Q3 2025 and 0.78 in Q2 2025.